Semaglutide for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on March 20th, 2026
|
Individuals with schizophrenia face a markedly elevated risk of premature mortality, largely driven by cardiovascular disease. Second-generation antipsychotics, particularly clozapine and olanzapine, are strongly associated with weight gain, insulin resistance, and other metabolic disturbances. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated efficacy in weight reduction and cardiovascular risk mitigation. A study published in the Journal of the American Medical Association evaluated whether semaglutide could improve metabolic parameters in patients with schizophrenia receiving antipsychotic therapy.
Funding Source(s): Government of Denmark
The trial enrolled 73 adults with schizophrenia spectrum disorders, with a median age of 35 years. Participants had been treated with either olanzapine or clozapine for approximately one to two years prior to enrollment. The cohort had a mean body mass index of approximately 36, consistent with obesity, although only about 5% had a formal diagnosis of type 2 diabetes. Baseline laboratory assessment showed a mean hemoglobin A1c level of 5.5%, indicating that most participants were not overtly diabetic at study entry.
Participants were randomly assigned to receive once-weekly subcutaneous injections of either placebo or semaglutide. The medication was initiated at 0.25 mg weekly, increased to 0.5 mg after four weeks, and escalated to 1.0 mg by week eight. Semaglutide exerts its metabolic effects through activation of GLP-1 receptors, leading to enhanced insulin secretion, suppression of glucagon release, delayed gastric emptying, increased satiety, and reduced appetite.
After 26 weeks, patients treated with semaglutide demonstrated significant reductions in hemoglobin A1c levels compared with placebo. Treatment was also associated with meaningful reductions in body weight, body mass index, and total fat mass. Additionally, exploratory findings suggested reductions in nicotine dependence and alcohol consumption among patients receiving semaglutide.
Given the small sample size and limited duration, larger trials with more balanced treatment allocation are needed to confirm these findings and further define the role of GLP-1 receptor agonists in managing antipsychotic-associated metabolic dysfunction in schizophrenia.
Funding Source(s): Government of Denmark
The trial enrolled 73 adults with schizophrenia spectrum disorders, with a median age of 35 years. Participants had been treated with either olanzapine or clozapine for approximately one to two years prior to enrollment. The cohort had a mean body mass index of approximately 36, consistent with obesity, although only about 5% had a formal diagnosis of type 2 diabetes. Baseline laboratory assessment showed a mean hemoglobin A1c level of 5.5%, indicating that most participants were not overtly diabetic at study entry.
Participants were randomly assigned to receive once-weekly subcutaneous injections of either placebo or semaglutide. The medication was initiated at 0.25 mg weekly, increased to 0.5 mg after four weeks, and escalated to 1.0 mg by week eight. Semaglutide exerts its metabolic effects through activation of GLP-1 receptors, leading to enhanced insulin secretion, suppression of glucagon release, delayed gastric emptying, increased satiety, and reduced appetite.
After 26 weeks, patients treated with semaglutide demonstrated significant reductions in hemoglobin A1c levels compared with placebo. Treatment was also associated with meaningful reductions in body weight, body mass index, and total fat mass. Additionally, exploratory findings suggested reductions in nicotine dependence and alcohol consumption among patients receiving semaglutide.
Given the small sample size and limited duration, larger trials with more balanced treatment allocation are needed to confirm these findings and further define the role of GLP-1 receptor agonists in managing antipsychotic-associated metabolic dysfunction in schizophrenia.